The effectiveness of A2AR antagonists in preclinical tumor models may be explained by the simultaneous targeting of multiple cell types (immune cells and non-immune cells) and biological processes (tumor growth, metastasis, and immune activation). The gene discussed is ADORA2A; the disease is neoplasm.